To the Editor:
Cell-free fetal DNA in the maternal circulation holds great potential for noninvasive prenatal diagnosis (1, 2 ) . However, the manual isolation of cell-free DNA from plasma can be a time-consuming process, and current techniques involving spin columns usually require multiple reloadings of the columns with sample material, increasing the risk of contamination (3) (4) (5) . Use of an automated system for DNA isolation can reduce the time involved, increase the throughput, and help reduce inconsistencies resulting from human error in processing of different plasma samples. We compared 2 techniques for extracting cell-free DNA from maternal plasma: the MagNA Pure TM LC Instrument (Roche Applied Science), an automated DNA isolation system; and a frequently used manual technique involving spin-column technology (High Pure PCR Template Preparation Kit TM ; Roche Diagnostics). After approval was granted from the Cantonal Institutional Review Board of Basel, we obtained 9 plasma samples from women carrying male fetuses (first to third trimester) to test the methods of DNA extraction. Identical samples were used for both methods, and the plasma was prepared according to our standard protocol and stored at Ϫ70°C (4, 5 ) . For the manual extraction method, cellfree DNA was extracted from 400 L of plasma according to the manufacturer's instructions and eluted with 100 L of elution buffer. For the automated method, DNA was extracted from 1000 L of plasma by the Roche MagNA Pure LC DNA Isolation Kit-Large Volume and eluted with 200 L of elution buffer. On the following day, we processed a second identical set of samples, using the same procedures as described above, which gave a total of 18 samples tested per method.
Total cell-free DNA was quantified by a real-time PCR assay for the ubiquitous glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene, whereas the amount of cell-free fetal DNA was assessed by use of the multicopy DYS14 sequence (6 ) . All concentrations are expressed as genome-equivalents (GE)/mL of maternal plasma (3 ). Our analysis revealed that manual extraction yielded 23.4% more total cell-free DNA than the automated method [mean (range), 2890 (797-10 060) GE/mL vs 2215 (620 -9010) GE/mL]. However, when we examined the quantity of cell-free fetal DNA obtained, we found that the automated system yielded 40.7% more cell-free fetal DNA than the manual method [mean (range), 86 (40 -204) GE/mL vs 51 (9 -160) GE/mL].
Another surprising finding was that the amplification efficiencies of the late cycles of the real-time PCR reactions appeared to be affected by the method used for DNA isolation, in that the steepness of the amplification curve was generally lower for the manually prepared samples than for the automated samples. This phenomenon became more evident when the amplification efficiencies of the late cycles were calculated from the slope of the amplification plots by the following equation:
An ideal, maximally efficient amplification reaction would have an efficiency value of 100%. For the samples prepared by the automated method, the mean E signal of amplification reactions for the GAPDH locus was 85%, whereas that for manually extracted samples was 73% (Fig. 1A) . The mean efficiency of the amplification reactions for the DYS14 locus for the automated preparations was 66%, whereas that for the manually prepared samples was 46% (Fig. 1B) . This finding may be attributable to the more thorough removal of inhibitors in the plasma samples by the automated DNA extraction method compared with the manual extraction method. The amplification efficiencies of diluted genomic DNA calibrators were Ն90% for both assays.
In summary, our data from this small exploratory study indicate that the extraction of cell-free DNA by automated means is not only less labor-intensive and more amenable to high-throughput analysis but may indeed provide material that is optimal for PCR analysis, in that it may contain fewer inhibitors. The more efficacious retrieval of cell-free fetal DNA compared with maternal DNA may reflect the molecular size differences that exist between maternal and fetal cell-free DNA (4, 7 ) . These aspects could be investigated further in a larger study. 
Unambiguous Identification of the Expressed MAGE-A Genes on a DNA Microarray

To the Editor:
We have described a post-PCR detection method for the 12 MAGE-A sequences on a DNA microarray (1 ) and compared the results with a method using pairs of primers unique for each sequence (2 ) . The microarray assay did not differentiate between MAGE-A3 and MAGE-A6 amplicons, which differed by only 1 nucleotide, and could not distinguish between PCR products amplified from mRNA and those amplified from genomic DNA. In addition, the assay could not identify false-negative results related to RNA degradation or to enzyme inhibition during reverse transcription-PCR.
Here we describe an assay that is designed to overcome these drawbacks and appears to be more sensitive. We used 3 primer pairs: 1 for amplification of the 12 MAGE-A sequences (1 ); 1 for specific amplification of MAGE-A3; and 1 for amplification of an endogenous, ubiquitously expressed control gene (MAGE-D2) (3 ). The low-density microarray includes new capture probes for MAGE-A3 and -D2. The assay involved DNase treatment of total RNA, reverse transcription of mRNA with oligo(dT) primer, triplex PCR amplification in the presence of biotin-dATP/biotin-dCTP, and hybridization of the resulting amplicons on a DNA microarray (see the Experimental Protocol in the Data Supplement that accompanies the online version of this Letter at http://www.clinchem.org/content/ vol51/issue12).
The new capture probe for MAGE-A3 corresponded to a sequence downstream from the location of the reverse primer DPASCONB4, and a primer pair (DPSA3 and DPASA3) defining a MAGE-A3 amplicon encompassing the new probe sequence was added to the PCR mixture. With a sample expressing MAGE-A3, this method generated 2 MAGE-A3 amplicons: one by extension of the consensus MAGE-A primers and the other by extension of the MAGE-A3 primers; only the latter, however, was detected on the microarray carrying the new MAGE-A3 probe. We verified the absence of cross-hybridization of MAGE-A6 sequences with the new MAGE-A3 probe by analyzing 8 tumor samples known to express MAGE-A6 but not MAGE-A3 (as determined by the comparison method). MAGE-A6 was detected in all samples, whereas no signal was detected with the MAGE-A3 probe in any sample.
To determine the detection limit of the assay, we tested various amounts (1.0, 0.1, 0.3, and 0.01 g) of DNasetreated total RNA from MZ2-MEL.3.0 cells. This melanoma cell line expresses MAGE-A1, -A2, -A3, -A6, and -A10 and weakly expresses MAGE-A5 and -A12 (2, 4 ) . With 1 g of RNA, all of the expected MAGE-A genes were detected (see Table 1 in the online Data Supplement). With Ͻ1 g RNA, only MAGE-A5 and -A12 were not detected. With 0.01 g of RNA, MAGE-A1, -A2, -A3, -A6, and -A10 were still detected. Compared with the previous microarray assay (1 ), the present results indicate an improvement in sensitivity by a factor of 10 for the detection of MAGE-A2, -A3, and -A10; by a factor of 33 for MAGE-A12; and by a factor of 100 for MAGE-A1 and -A6. This improvement probably results from the labeling of the amplicons with 2 nucleotides (biotin-11-dATP and biotin-11-dCTP) rather than biotin-16-dUTP alone (1 ).
We analyzed 52 cDNA samples from tumor tissues and cell lines. Two independent PCR amplifications were performed on each cDNA sample, and the resulting products were hybridized on separate microarrays. For genes MAGE-A1, -A2, -A3, -A4, -A6, -A10, or -A12, we observed a 100% correlation between the results of the 2 methods when the gene expression determined with the comparison method was Ͼ10% of that found in the reference cell line and a 98.3% correlation when no expression was detected with the comparison method (Table 1) . Discrepancies were observed only for MAGE-A12 in 3 samples. A possible explanation for the negative results by the comparison PCR assay is that MAGE-A12 is not detected optimally because the sequence of the sense primer is located close to the 5Ј end of the first exon of MAGE-A12. The sensitivity of this assay could be improved by selecting sense and antisense primers in the last exon of MAGE-A12 (F. Brasseur, personal communication). In the MAGECHIP ® assay, the MAGE-A12
